FDA Determines Regulatory Review Period for Celexa Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of Celexa, a human drug product, in accordance with federal regulations and in response to a formal application submitted to the US Department of Commerce.